Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease.
Aged
Aged, 80 and over
Biomarkers
/ blood
Case-Control Studies
Cross-Sectional Studies
Cytokines
/ blood
Diabetes Mellitus, Type 2
/ blood
Diabetic Angiopathies
/ blood
Down-Regulation
Female
GPI-Linked Proteins
/ blood
Humans
Lectins
/ blood
Male
Middle Aged
Peripheral Arterial Disease
/ blood
Severity of Illness Index
Atherosclerosis
Omentin-1
Peripheral artery disease (PAD)
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
05 06 2019
05 06 2019
Historique:
received:
29
03
2019
accepted:
30
05
2019
entrez:
7
6
2019
pubmed:
7
6
2019
medline:
25
2
2020
Statut:
epublish
Résumé
Type-2 diabetes mellitus is one of the major risk factors of atherosclerosis, particularly in peripheral artery disease (PAD). Several studies have documented a correlation between omentin-1 serum levels, atherosclerosis, and cardiovascular diseases. However, a clear link between circulating omentin-1 and PAD in diabetic patients has yet to be established. The aim of this study was to investigate the potential role of omentin-1 in PAD in type-2 diabetic patients. In this cross-sectional study, we analyzed omentin-1 serum levels by ELISA in 600 type-2 diabetic patients with (n = 300) and without (n = 300) PAD at Fontaine's stage II, III, or IV. We found that omentin-1 serum levels were significantly lower in diabetic patients with PAD than in diabetic controls (29.46 vs 49.24 ng/mL, P < 0.001) and that the levels gradually decreased in proportion to disease severity (P < 0.05). The association between omentin-1 levels and PAD remained significant after adjusting for major risk factors in a multivariate analysis. Our results suggest that omentin-1 is reduced in type 2 diabetic patients with PAD and that omentin-1 levels are related to disease severity.
Sections du résumé
BACKGROUND
Type-2 diabetes mellitus is one of the major risk factors of atherosclerosis, particularly in peripheral artery disease (PAD). Several studies have documented a correlation between omentin-1 serum levels, atherosclerosis, and cardiovascular diseases. However, a clear link between circulating omentin-1 and PAD in diabetic patients has yet to be established. The aim of this study was to investigate the potential role of omentin-1 in PAD in type-2 diabetic patients.
METHODS
In this cross-sectional study, we analyzed omentin-1 serum levels by ELISA in 600 type-2 diabetic patients with (n = 300) and without (n = 300) PAD at Fontaine's stage II, III, or IV.
RESULTS
We found that omentin-1 serum levels were significantly lower in diabetic patients with PAD than in diabetic controls (29.46 vs 49.24 ng/mL, P < 0.001) and that the levels gradually decreased in proportion to disease severity (P < 0.05). The association between omentin-1 levels and PAD remained significant after adjusting for major risk factors in a multivariate analysis.
CONCLUSIONS
Our results suggest that omentin-1 is reduced in type 2 diabetic patients with PAD and that omentin-1 levels are related to disease severity.
Identifiants
pubmed: 31167666
doi: 10.1186/s12933-019-0880-7
pii: 10.1186/s12933-019-0880-7
pmc: PMC6549359
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
GPI-Linked Proteins
0
ITLN1 protein, human
0
Lectins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Références
Diabetes. 2004 Jan;53(1):228-34
pubmed: 14693720
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Cardiovasc Diabetol. 2011 Nov 22;10:103
pubmed: 22108456
Diabetes. 2007 Jun;56(6):1655-61
pubmed: 17329619
Circulation. 2017 Mar 21;135(12):e726-e779
pubmed: 27840333
Asian Cardiovasc Thorac Ann. 2017 Mar;25(3):199-203
pubmed: 28325076
Cardiovasc Diabetol. 2018 Oct 10;17(1):134
pubmed: 30305178
J Am Coll Cardiol. 2018 May 22;71(20):2306-2315
pubmed: 29540326
Int Angiol. 2014 Oct;33(5):455-60
pubmed: 25294287
Obes Facts. 2017;10(4):323-331
pubmed: 28787708
Eur Heart J. 2013 Sep;34(34):2706-14
pubmed: 23864133
Diabetes Care. 2003 Dec;26(12):3333-41
pubmed: 14633825
Eur J Vasc Endovasc Surg. 2011 Jan;41(1):110-6
pubmed: 21095144
Cardiovasc Diabetol. 2017 Jul 7;16(1):87
pubmed: 28687077
J Diabetes Complications. 2016 May-Jun;30(4):738-45
pubmed: 26781070
J Am Coll Cardiol. 2006 Mar 7;47(5):921-9
pubmed: 16516072
Cardiovasc Diabetol. 2014 Apr 23;13:84
pubmed: 24755035
Trends Endocrinol Metab. 2014 Jul;25(7):348-55
pubmed: 24746980
Cardiovasc Diabetol. 2017 Oct 16;16(1):133
pubmed: 29037197
Atherosclerosis. 2016 Aug;251:415-421
pubmed: 27298015
Curr Vasc Pharmacol. 2018;16(6):547-554
pubmed: 28762307
PLoS One. 2017 Oct 26;12(10):e0186220
pubmed: 29073236
Cardiovasc Res. 2016 May 1;110(1):1-3
pubmed: 26935810
Gynecol Endocrinol. 2012 Jul;28(7):521-4
pubmed: 22309615
Ann Endocrinol (Paris). 2014 Jul;75(3):171-5
pubmed: 24997770
Compr Physiol. 2017 Jun 18;7(3):765-781
pubmed: 28640441
Int Angiol. 1985 Jul-Sep;4(3):311-22
pubmed: 2937858
Clin Chem Lab Med. 2013 Jan;51(1):177-85
pubmed: 23241684
Diabetes Res Clin Pract. 2019 Feb;148:160-168
pubmed: 30641171
Mediators Inflamm. 2010;2010:535918
pubmed: 20847813
Lancet. 2013 Oct 19;382(9901):1329-40
pubmed: 23915883
Biol Pharm Bull. 2011;34(3):307-10
pubmed: 21372376
J Clin Transl Endocrinol. 2018 May 31;13:14-19
pubmed: 30023310
Cytokine. 2019 Jul;119:144-151
pubmed: 30909150
Diabetes Res Clin Pract. 2011 Jul;93(1):21-5
pubmed: 21497934